Business Wire

IPROOV

29.7.2021 06:03:04 CEST | Business Wire | Press release

Share
iProov Achieves Record-breaking Growth as Demand for Genuine Presence Assurance™ Soars

iProov , world leader in secure biometric authentication technology, today announced record-breaking growth in the first half of 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210728006091/en/

From January to June 2021, iProov saw a 15x increase in the number of people verified using its technology versus the same time period last year. Its flagship Genuine Presence Assurance technology solidified its global market leadership, with verifications growing at a consistent rate of 25% per month worldwide.

This has been driven by demand from organizations needing to verify the identity of online users to prevent fraud. iProov’s patented technology assures the genuine presence of an online user to ensure they are the right person, a real person, and authenticating right now.

iProov has been profitable in 2021, while at the same time growing its worldwide team by 25% to 85 staff. In April, the company welcomed cybersecurity veteran Paul King who joined iProov’s advisory board following 27 years at Cisco, most recently as Chief Security Officer. iProov has also been awarded numerous prestigious awards, including Best Biometric Solution at the 2021 Cyber Security Global Excellence Awards.

In what has been a tumultuous year across the globe, iProov’s technology has provided safe and secure digital identity verification for a growing range of vital services. Since the start of 2021, iProov has added major customers and partners to its portfolio spanning government, health, travel, financial services and ID providers.

In February iProov announced it had been selected by the Australian government to provide the liveness solution for myGovID. Millions of Australians will be able to strengthen their digital identity using a simple face scan on their mobiles, providing access to a range of government services, including online tax.

iProov’s existing service to NHS Digital in the UK became even more crucial this year. Since 2020, iProov has enabled users in England to create an NHS login remotely and securely. A user scans their identity document, such as a valid passport or driver’s license, and then completes a brief iProov face verification to confirm their identity, giving them secure access to the services of the NHS App. Since May 2021, this has included the COVID vaccination status service.

In January 2021, iProov announced a collaboration with its partner, Mvine, to trial private COVID status certificates. The solution enables an individual to register a test result or vaccination status and then securely share that status without disclosing their identity, using either paper or a smartphone. The trials, which took place in care and education settings, were backed by investment from Innovate UK and showcased how biometric verification could greatly simplify the checking of COVID status credentials while enhancing user privacy.

The iProov partner program grew by a third in the first six months of the year, from sectors including identity, health, travel and cryptocurrency. In April, Jumio, the leading provider of AI-powered end-to-end identity verification and eKYC solutions, announced that it had selected iProov technology to deliver high conversion rates, fast onboarding, a natural user experience and small SDK size to its customers.

Andrew Bud, iProov Founder and CEO, commented: “In the first half of 2021, iProov has secured users’ identities online and protected major organizations from fraud on a vast scale across the globe. The dramatic acceleration in the digital identity market, caused by the pandemic, has demonstrated our market leadership based on our unrivaled usability, inclusiveness and resilient security, and the extraordinary scalability of our platform. I am continually impressed by the remarkable work of the iProov team in successfully rising to the many challenges created by such transformative growth.”

The highlights from 2021 so far include: -

Awards

● iProov Takes Home Gold in Three Cybersecurity Excellence Awards: Government, Financial Services, and Identity Proofing & Corroboration - https://www.iproov.com/blog/cyber-security-awards-government-finance

● iProov wins Best Biometric Solution at 2021 Cyber Security Global Excellence Awards - https://www.iproov.com/blog/best-biometric-solution-cyber-security-2021

● iProov Named Winner of Coveted Global InfoSec Award During RSA Conference - https://www.iproov.com/press/iproov-winner-of-global-infosec-award-during-rsa-conference-2021

Customers and partners

● Australian Taxation Office extends national digital identity program with face verification technology from iProov - https://www.iproov.com/press/australian-taxation-office-national-digital-identity-program-face-verification-technology

● Jumio adds iProov’s award winning liveness detection to its KYC platform - https://www.iproov.com/press/jumio-adds-iproov-award-winning-liveness-detection-to-its-kyx-platform

● iProov selected by itsme to support global expansion - https://www.iproov.com/press/iproov-face-verification-selected-by-itsme-to-support-global-expansion

● COVID-19 certificate solution from iProov and Mvine moves into trial phase - https://www.iproov.com/press/uk-covid19-passport-moves-into-trial-phase

Senior team hires

● Cybersecurity veteran Paul King joins iProov’s Advisory Board - https://www.iproov.com/press/cyber-security-veteran-joins-iproov-advisory-board

-ENDS-

About iProov

Founded in 2012, iProov is the world leader in online facial biometric authentication, working with governments, financial institutions and other enterprises to securely verify customer identity. Used for effortless onboarding and authentication, customers include the U.S. Department of Homeland Security, the UK Home Office, the UK National Health Service (NHS), the Australian Taxation Office, GovTech Singapore, Rabobank, ING and others. iProov’s technologies include Liveness Assurance and Genuine Presence Assurance, which ensures that an online customer is the right person, a real person, and is authenticating right now. This protects against spoof attacks from photos, videos, masks and digital injection attacks that use deepfakes and other synthetic media. Supported by capital from private equity firm JRJ Group, iProov has grown a global footprint with offices in the UK, US and Singapore. iProov was recognized as a Gartner Cool Vendor 2020 in Identity Access Management & Fraud Detection and as the 5th fastest growing technology company in the UK in the Deloitte 2020 UK Technology Fast 50. For more information, please see www.iproov.com or follow us on LinkedIn or Twitter.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 15:00:00 CEST | Press release

Enterprise software veteran to lead Tacton’s united commercial organization and partner expansion worldwide. Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led

EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 15:00:00 CEST | Press release

European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea

ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 14:00:00 CEST | Press release

Intranasal pertussis vaccine candidate BPZE1 demonstrates robust nasal mucosal and systemic immune responses with a favorable safety profile in children ages 6 through 17 yearsFirst pediatric clinical trial builds on 5 prior adult BPZE1 clinical studiesDemonstrates safety and immunogenicity of BPZE1 in acellular pertussis vaccine primed individualsNo interference observed when BPZE1 co-administered with diphtheria and tetanus antigens ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The stu

NIQ Brings New AI and Automation Capabilities to Retail Space Planning and Merchandising2.10.2026 12:45:00 CEST | Press release

New AI and automation capabilities help retailers close execution gaps and scale merchandising decisions across every store. NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced new AI and automation capabilities for NIQ Spaceman®, its retail space planning and merchandising platform trusted by more than 600 retailers across 65+ countries. The enhancements help retailers create store-specific planograms up to 50 times faster, identify execution and compliance gaps, and scale merchandising decisions across their store networks through expanded cloud-based access. "Retailers are under increasing pressure to localize assortments, execute consistently across stores, and respond more quickly to changing shopper behavior," said Natalie Williams, SVP, Product at NIQ. "These enhancements help simplify that process by embedding agentic AI directly into merchandising workflows and automating traditionally manual planning tasks. That means teams can spend less time buil

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2.10.2026 12:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to one senior leader and ten newly hired non-executive employees. The equity awards for the senior leader were granted on September 30, 2026 and consisted of options to purchase an aggregate of 121,800 shares and restricted share units covering an aggregate of 58,000 shares. The options have an exercise price per share equal to $12.44. The equity awards to the ten newly hired non-executive employees were granted on October 1, 2026 and consisted of options to purchase an aggregate of 97,100 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 46,200 shares. These options have an exercise price per share equal to $11.95, the closing price of the Company’s American De

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye